AIRNA: $155 Million (Series B) Secured For RNA Editing Therapeutics
By Amit Chowdhry ● Apr 1, 2025
AIRNA, a biotech company pioneering RNA editing therapeutics to transform patients' lives with rare and common conditions, announced the closing of an oversubscribed $155 million Series B financing. The funding was led by Venrock Healthcare Capital Partners, co-led by Forbion Growth, and included participation from RTW Investments, Nextech Invest, ARCH Venture Partners, Forbion Ventures, ND Capital, and other new and existing investors.